Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,225 stopped studies mapped to Malignant Genitourinary System Neoplasm and descendants · 88% state a reason
Over the 2,225 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02588404 | The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient | — | withdrawn | Oct 27, 2015 | Sir Mortimer B. Davis - Jewish General Hospital | not stated | Not stated |
| NCT05826470 | Investigator Initiated Trial to Further Evaluate the Safety and Efficacy of… | N/A | terminated | Apr 24, 2023 | Genesis Research LLC | Business decision of the Sponsor | Sponsor / business decision |
| NCT04064190 | Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition | Phase 2 | withdrawn | Aug 21, 2019 | MedPacto, Inc. | Changing trial strategy | Sponsor / business decision |
| NCT04826198 | Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in…(REVOCAN) | Phase 1 / Phase 2 | terminated | Apr 1, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Treatment availability issue: The manufacturer of AsiDNA™ decided to cease production to develop an… | Drug supply |
| NCT05119010 | A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in…(KETOREIN) | N/A | terminated | Nov 12, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Recruitment challenges: competition with another microbiome trial, patient refusal to join a… | Enrollment / accrual |
| NCT05744128 | CD8 Minibody Repeatability Study(PRETZCEL) | Phase 2 | terminated | Feb 24, 2023 | ImaginAb, Inc. | Strategic decision | Sponsor / business decision |
| NCT04530019 | Brachytherapy Innovations in Gynecologic Cancer | — | withdrawn | Aug 28, 2020 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study never opened. | Other (stated, no rule matched) |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT05418387 | A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer… | N/A | withdrawn | Jun 14, 2022 | University of Arizona | The study will be withdrawn as the Principal Investigator, Ken Batai, left the institution prior to… | Investigator |
| NCT03514121 | FPA150 in Patients With Advanced Solid Tumors(FPA150-001) | Early Phase 1 | terminated | May 2, 2018 | Five Prime Therapeutics, Inc. | The Sponsor terminated the study for reasons unrelated to safety. | Safety / toxicity |
| NCT06390111 | A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects…(ABLE-42) | Phase 4 | withdrawn | Apr 30, 2024 | Ferring Pharmaceuticals | Ferring decided to prioritize collection of ADSTILADRIN re-induction data in patients with HR… | Other (stated, no rule matched) |
| NCT03486197 | Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced… | Phase 2 | terminated | Apr 3, 2018 | University of Washington | Closed per SRC Low Accrual Policy | Enrollment / accrual |
| NCT05261490 | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With… | Phase 1 / Phase 2 | terminated | Mar 2, 2022 | Pfizer | A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study… | Safety / toxicity |
| NCT02588846 | Multi-target Tracking in Prostate Radiotherapy Using MLC and KIM(KOALA) | N/A | withdrawn | Oct 28, 2015 | Royal North Shore Hospital | no resources to run the trial | Other (stated, no rule matched) |
| NCT04493619 | PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With… | Phase 1 / Phase 2 | terminated | Jul 30, 2020 | Opna Bio LLC | study terminated due to business realignment | Sponsor / business decision |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With… | Phase 1 | terminated | Sep 13, 2023 | Molecular Templates, Inc. | Sponsor Termination | Other (stated, no rule matched) |
| NCT03990194 | Real-life Study of Patients After 3-months of Leuprorelin 5mg Implant in Prostate Cancer(LEPTO) | — | withdrawn | Jun 18, 2019 | RECORDATI GROUP | Internal decision | Other (stated, no rule matched) |
| NCT06218667 | A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer | Phase 1 / Phase 2 | withdrawn | Jan 23, 2024 | Memorial Sloan Kettering Cancer Center | Study drug not available per sponsor | Other (stated, no rule matched) |
| NCT03393936 | Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage… | Phase 1 / Phase 2 | terminated | Jan 9, 2018 | Shanghai PerHum Therapeutics Co., Ltd. | Adjustment of study strategy | Sponsor / business decision |
| NCT03960060 | A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid…(CAR) | Phase 1 | terminated | May 22, 2019 | Shanghai PerHum Therapeutics Co., Ltd. | Adjustment of study strategy | Sponsor / business decision |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in…(VELIA) | Phase 3 | terminated | Jun 12, 2015 | AbbVie | Business decision not related to patient safety | Safety / toxicity |
| NCT04580836 | MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK… | Phase 2 | withdrawn | Oct 9, 2020 | M.D. Anderson Cancer Center | A study with 0 ACTUAL Enrollment must have Overall Recruitment Status specified as Withdrawn | Enrollment / accrual |
| NCT04690699 | LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without… | Phase 1 / Phase 2 | terminated | Dec 31, 2020 | Istari Oncology, Inc. | business decision | Sponsor / business decision |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors…(PDL1x41BB) | Phase 1 | terminated | Jan 18, 2019 | Inhibrx Biosciences, Inc | Program terminated due to lack of meaningful efficacy signal. | Efficacy / futility |
| NCT06016504 | Adaptive Virtual Consultation Tool to Enhance Education and Understanding in Patients… | N/A | terminated | Aug 29, 2023 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT03240523 | A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 5) | Phase 3 | terminated | Aug 7, 2017 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
| NCT04291664 | PK and Dose Escalation and Expansion Study of DST-2970 | Phase 1 | terminated | Mar 2, 2020 | DisperSol Technologies, LLC | Dose escalation portion of the study completed, one expansion cohort was eliminated due to change… | Enrollment / accrual |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03238053 | Laser Treatment of Genito-urinary Syndrome in Women | N/A | withdrawn | Aug 3, 2017 | Herning Hospital | Hospital terminated treatment with laser | Other (stated, no rule matched) |
| NCT04923672 | Exercise Preconditioning with Cancer Surgeries(ExPre 01) | N/A | terminated | Jun 11, 2021 | University of Virginia | Company providing the computer application for exercise intervention suddenly closed for business | Sponsor / business decision |
| NCT04583553 | Comparative Microbial Analysis of Cystitis in Non-muscle-invasive Bladder Cancer Patients…(VS-UrineID) | — | withdrawn | Oct 12, 2020 | University of Kansas Medical Center | Site did not proceed with study. | Other (stated, no rule matched) |
| NCT06161493 | ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors | Phase 1 | withdrawn | Dec 8, 2023 | Haider Mahdi | Investigator Discretion | Investigator |
| NCT03821376 | Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS) | Phase 4 | terminated | Jan 29, 2019 | Indiana University | Study stopped due to staffing issues that impacted ability to recruit. | Enrollment / accrual |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and… | Phase 2 | terminated | Jul 5, 2017 | Novartis Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT05156905 | Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate… | Phase 1 | terminated | Dec 14, 2021 | University of California, San Diego | Oncternal closing clinical trial operations. | Other (stated, no rule matched) |
| NCT04312191 | Using Meditation for Oncology Anxiety | N/A | withdrawn | Mar 18, 2020 | Mellar Davis MD | Study was not started and PI is retiring. | Other (stated, no rule matched) |
| NCT05846165 | InveStigAting Bladder fiELd-cycLing imAging(ISABELLA) | N/A | withdrawn | May 6, 2023 | University of Aberdeen | No participants identified. Funding ended | Funding |
| NCT06424717 | Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has… | Phase 2 | withdrawn | May 22, 2024 | EMD Serono Research & Development Institute, Inc. | Trial withdrawn based on re-prioritization of the clinical development path for tuvusertib. No… | Enrollment / accrual |
| NCT03177187 | Combination Study of AZD5069 and Enzalutamide.(ACE) | Phase 1 / Phase 2 | terminated | Jun 6, 2017 | Institute of Cancer Research, United Kingdom | Discontinuation of production of IMP | Other (stated, no rule matched) |
| NCT03677024 | Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk… | N/A | withdrawn | Sep 19, 2018 | Fudan University | This study was not approved by the Ethics Committee | Other (stated, no rule matched) |
| NCT06068738 | Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer(EXCYTE-1) | — | terminated | Oct 5, 2023 | Exscientia AI Limited | Study was terminated due to a strategic re-evaluation of the company's overall business and… | Sponsor / business decision |
| NCT05707182 | 18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study | Early Phase 1 | withdrawn | Jan 31, 2023 | University of Alabama at Birmingham | Recruitment was difficult. | Enrollment / accrual |
| NCT06099418 | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With… | Phase 2 | withdrawn | Oct 25, 2023 | Nykode Therapeutics ASA | Trial VB-C-04 was stopped due to company strategic reasons and recent changes in standard of care… | Sponsor / business decision |
| NCT03459755 | Evaluating Race Specific AGE Accumulation As a Behavioral Biomarker Prostate Cancer… | N/A | withdrawn | Mar 9, 2018 | Medical University of South Carolina | investigator decision | Investigator |
| NCT03493464 | BR55 in Characterization of Ovarian Lesions | Phase 2 | terminated | Apr 10, 2018 | Bracco Diagnostics, Inc | Sponsor decision; expiration of available study agent due to long recruitment timeline. | Enrollment / accrual |
| NCT03691376 | Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan… | Phase 1 | terminated | Oct 1, 2018 | Roswell Park Cancer Institute | Lack of funding | Funding |
| NCT03777982 | Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate +… | Phase 3 | terminated | Dec 19, 2018 | Dana-Farber Cancer Institute | PI is terminating the study due to slow/low accrual | Enrollment / accrual |
| NCT05641545 | IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint… | Phase 1 | terminated | Dec 7, 2022 | SLK Kliniken Heilbronn GmbH | Premature discontinuation due to üoor participant recruitment | Enrollment / accrual |
| NCT05655598 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | Phase 1 | withdrawn | Dec 19, 2022 | Brown University | Lack of accrual | Enrollment / accrual |
| NCT05679388 | A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or… | Phase 1 | terminated | Jan 11, 2023 | University of Chicago | Terminated by the PI | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Dec 10, 2024source: clinicaltrials